Eustolia sells EXAS 18.9: On average, analysts predict that EXACT Sciences will post $-1.74 earnings per share for the current fiscal year.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Monday, July 20th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company. Finally, analysts at William Blair reiterated an outperform rating on shares of EXACT Sciences in a research note on Saturday, June 27th. Analysts at Benchmark Co. reiterated a buy rating and set a $34.00 price target (up previously from $31.00) on shares of EXACT Sciences in a research note on Tuesday, July 21st. Analysts at Mizuho reiterated a positive rating and set a $35.00 price target on shares of EXACT Sciences in a research note on Tuesday, July 21st.


Dori:
Analysts at Roth Capital reiterated a buy rating on shares of EXACT Sciences in a research note on Tuesday, July 21st.

Bryanna:
The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.01. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $7.96 million.

Blanche:
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Monday, July 20th.

Lera:
Analysts expect that EXACT Sciences will post $-1.74 EPS for the current fiscal year.

Mahalia:
One analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the stock.

Lorean:
Analysts at Canaccord Genuity reiterated a buy rating on shares of EXACT Sciences in a research note on Sunday, June 28th.

Earlene:
Analysts at Lake Street Capital reiterated a hold rating and set a $27.00 price target (up previously from $24.00) on shares of EXACT Sciences in a research note on Monday, June 29th.

Gilma:
Analysts at Roth Capital raised their price target on shares of EXACT Sciences from $28.00 to $31.00 and gave the company a buy rating in a research note on Monday, July 13th.

Shakita:
Analysts at Benchmark Co. reiterated a buy rating and set a $34.00 price target (up previously from $31.00) on shares of EXACT Sciences in a research note on Tuesday.

Janessa:
The firm currently has a $35.00 price target on the stock.

Exact Sciences Corp. (NASDAQ:EXAS)
//stockhand.net/us/?q=nasdaq%3Aexas&id=57884